New combo shows promise for Tough-to-Treat lung cancer
NCT ID NCT05941897
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a combination of two drugs—ceralasertib (a pill) and durvalumab (an infusion)—in 39 adults with advanced or metastatic non-small cell lung cancer that has worsened after standard treatments like immunotherapy and chemotherapy. The main goal is to see if the combination can shrink tumors. Researchers will also track how long any response lasts and how quickly it occurs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ceralasertib and durvalumab
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced lung cancer who have run out of standard therapies.
- What could go wrong
- This is a small, early-phase trial with only 39 participants and no comparison group, so results may not be conclusive. The combination may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Moscow, 111123, Russia
-
Research Site
Moscow, 115478, Russia
-
Research Site
Moscow, 115533, Russia
-
Research Site
Moscow, 125284, Russia
-
Research Site
Moscow, 143423, Russia
-
Research Site
Nizhny Novgorod, 603126, Russia
-
Research Site
Saint Petersburg, 197758, Russia
-
Research Site
Saint Petersburg, 198255, Russia
More trials for these conditions
Other studies related to the condition(s) this trial covers.